Verrica Pharmaceuticals Inc. Operating Lease Cost
Verrica Pharmaceuticals Inc. (VRCA) reported Operating Lease Cost of $85.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. operating lease, cost for the quarter ending 2026-06-30 was $85.00K, a 0.00% change year-over-year.
- Verrica Pharmaceuticals Inc. operating lease, cost for the quarter ending 2026-03-31 was $85.00K, a 0.00% change year-over-year.
- Verrica Pharmaceuticals Inc. operating lease, cost for the quarter ending 2025-12-31 was $85.00K, a 10.53% decline year-over-year.
- Verrica Pharmaceuticals Inc. operating lease, cost for the quarter ending 2025-09-30 was $85.00K, a 13.27% decline year-over-year.
- Verrica Pharmaceuticals Inc. operating lease, cost for fiscal 2025 was $341.00K, a 11.89% decline from fiscal 2024.
- Verrica Pharmaceuticals Inc. operating lease, cost for fiscal 2024 was $387.00K, a 37.23% increase from fiscal 2023.
- Verrica Pharmaceuticals Inc. operating lease, cost for fiscal 2023 was $282.00K, a 23.58% decline from fiscal 2022.
- Verrica Pharmaceuticals Inc. operating lease, cost for fiscal 2022 was $369.00K, a 6.65% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $85.00K 10-Q · filed 2026-08-06 | $171.00K 10-Q · filed 2026-08-06 | $255.00K derived: sum of 3 quarters · filed 2026-08-06 | $340.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $85.00K 10-Q · filed 2026-05-12 | $170.00K derived: sum of 2 quarters · filed 2026-05-12 | $255.00K derived: sum of 3 quarters · filed 2026-05-12 | $340.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $170.00K derived: sum of 2 quarters · filed 2026-03-11 | $255.00K derived: sum of 3 quarters · filed 2026-08-06 | $341.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $85.00K 10-Q · filed 2025-11-14 | $170.00K derived: sum of 2 quarters · filed 2026-08-06 | $256.00K 10-Q · filed 2025-11-14 | $350.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $85.00K 10-Q · filed 2026-08-06 | $171.00K 10-Q · filed 2026-08-06 | $265.00K derived: sum of 3 quarters · filed 2026-08-06 | $363.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $85.00K 10-Q · filed 2026-05-12 | $180.00K derived: sum of 2 quarters · filed 2026-05-12 | $278.00K derived: sum of 3 quarters · filed 2026-05-12 | $375.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $193.00K derived: sum of 2 quarters · filed 2026-03-11 | $290.00K derived: sum of 3 quarters · filed 2026-03-11 | $387.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | $98.00K 10-Q · filed 2025-11-14 | $195.00K derived: sum of 2 quarters · filed 2025-11-14 | $292.00K 10-Q · filed 2025-11-14 | $293.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $97.00K 10-Q · filed 2025-08-12 | $194.00K 10-Q · filed 2025-08-12 | $195.00K derived: sum of 3 quarters · filed 2025-08-12 | $288.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $94.00K 10-Q · filed 2025-05-13 | $98.00K derived: sum of 2 quarters · filed 2025-05-13 | $191.00K derived: sum of 3 quarters · filed 2025-05-13 | $226.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $97.00K derived: sum of 2 quarters · filed 2025-03-11 | $132.00K derived: sum of 3 quarters · filed 2025-03-11 | $282.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $93.00K 10-Q · filed 2024-11-05 | $128.00K derived: sum of 2 quarters · filed 2024-11-05 | $278.00K 10-Q · filed 2024-11-05 | $311.00K derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $35.00K 10-Q · filed 2024-08-14 | $71.00K 10-Q · filed 2024-08-14 | $218.00K derived: sum of 3 quarters · filed 2024-08-14 | $313.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $86.00K 10-Q · filed 2024-05-13 | $183.00K derived: sum of 2 quarters · filed 2024-05-13 | $278.00K derived: sum of 3 quarters · filed 2024-05-13 | $368.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $192.00K derived: sum of 2 quarters · filed 2024-02-29 | $282.00K derived: sum of 3 quarters · filed 2024-02-29 | $369.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $95.00K 10-Q · filed 2023-11-09 | $185.00K derived: sum of 2 quarters · filed 2023-11-09 | $272.00K 10-Q · filed 2023-11-09 | $356.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $90.00K 10-Q · filed 2023-08-08 | $175.00K 10-Q · filed 2023-08-08 | $261.00K derived: sum of 3 quarters · filed 2023-08-08 | $346.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $85.00K 10-Q · filed 2023-05-09 | $171.00K derived: sum of 2 quarters · filed 2023-05-09 | $256.00K derived: sum of 3 quarters · filed 2023-05-09 | $340.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $171.00K derived: sum of 2 quarters · filed 2023-03-06 | $255.00K derived: sum of 3 quarters · filed 2023-03-06 | $346.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $85.00K 10-Q · filed 2022-11-07 | $169.00K derived: sum of 2 quarters · filed 2022-11-07 | $260.00K 10-Q · filed 2022-11-07 | $281.00K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $84.00K 10-Q · filed 2022-08-11 | $175.00K 10-Q · filed 2022-08-11 | $196.00K derived: sum of 3 quarters · filed 2022-08-11 | $231.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $89.00K 10-Q · filed 2022-05-09 | $112.00K derived: sum of 2 quarters · filed 2022-05-09 | $147.00K derived: sum of 3 quarters · filed 2022-05-09 | $194.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $58.00K derived: sum of 2 quarters · filed 2022-03-02 | $105.00K derived: sum of 3 quarters · filed 2022-03-02 | $164.00K 10-K · filed 2022-03-02 |
| 2020-09-30 | $35.00K 10-Q · filed 2021-11-12 | $82.00K derived: sum of 2 quarters · filed 2021-11-12 | $141.00K 10-Q · filed 2021-11-12 | $199.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $47.00K 10-Q · filed 2021-08-10 | $105.00K 10-Q · filed 2021-08-10 | $164.00K derived: sum of 3 quarters · filed 2021-08-10 | $235.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $58.00K 10-Q · filed 2021-05-07 | $117.00K derived: sum of 2 quarters · filed 2021-05-07 | $188.00K derived: sum of 3 quarters · filed 2021-05-07 | $235.00K derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $130.00K derived: sum of 2 quarters · filed 2021-03-17 | $177.00K derived: sum of 3 quarters · filed 2021-03-17 | $211.00K 10-K · filed 2021-03-17 |
| 2019-09-30 | $71.00K 10-Q · filed 2020-11-09 | $118.00K derived: sum of 2 quarters · filed 2020-11-09 | $152.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $47.00K 10-Q · filed 2020-08-05 | $81.00K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $34.00K 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $98.00K 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |